News und Analysen
![Xencor Reports Second Quarter 2020 Financial Results](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Xencor Reports Second Quarter 2020 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported financial
![Acadia Healthcare Reports Second Quarter 2020 Results](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Acadia Healthcare Reports Second Quarter 2020 Results
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the second quarter ended June 30, 2020.
The Company reported revenue of $750.3 million for the second quarter
![Premier Inc. ProvideGx® Program Partners with Somerset Pharma to Stabilize Pricing, Enhance Competition for Sulfamethoxazole/Trimethoprim](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Premier Inc. ProvideGx® Program Partners with Somerset Pharma to Stabilize Pricing, Enhance Competition for Sulfamethoxazole/Trimethoprim
Premier Inc. (NASDAQ: PINC), through its ProvideGx® program, has partnered with Somerset Pharma, LLC., to supply sulfamethoxazole/trimethoprim, an antibiotic combination used to treat respiratory
![Xencor Earns Milestone Payment from MorphoSys for FDA Approval of Monjuvi® (tafasitamab-cxix) in the United States](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Xencor Earns Milestone Payment from MorphoSys for FDA Approval of Monjuvi® (tafasitamab-cxix) in the United States
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, announced that the U.S. Food
![Premier Healthcare Database Being Used by National Institutes of Health to Evaluate Impact of COVID-19 on Patients Across the U.S.](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Premier Healthcare Database Being Used by National Institutes of Health to Evaluate Impact of COVID-19 on Patients Across the U.S.
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today announced a data licensing agreement with the National Institutes of Health (NIH). Under the terms of the agreement
![Novocure Reports Second Quarter 2020 Financial Results and Provides Company Update](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Novocure Reports Second Quarter 2020 Financial Results and Provides Company Update
Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2020, highlighting revenue growth and financial strength as well as the advancement of the company’s clinical
![Chemed Reports Second-Quarter 2020 Results](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Chemed Reports Second-Quarter 2020 Results
Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest
![Premier Inc. Technology Predicts Number of COVID-19 Cases in U.S. Hospitals in Near Real Time](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Premier Inc. Technology Predicts Number of COVID-19 Cases in U.S. Hospitals in Near Real Time
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, has enhanced its crisis forecasting and planning technology to predict the COVID-19 census for any U.S. hospital on a given
![Xencor to Host Second Quarter 2020 Financial Results Webcast and Conference Call on August 4, 2020](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Xencor to Host Second Quarter 2020 Financial Results Webcast and Conference Call on August 4, 2020
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that it will
![Premier, Inc. to Report Fiscal 2020 Fourth-Quarter and Full-Year Results and Host Conference Call on August 25, 2020](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Premier, Inc. to Report Fiscal 2020 Fourth-Quarter and Full-Year Results and Host Conference Call on August 25, 2020
Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2020 fourth quarter and full year on Tuesday, August 25, 2020, at approximately 6:30 a.m. EDT. The
![Novocure Announces Recipients of 2nd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Novocure Announces Recipients of 2nd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
Novocure (NASDAQ:NVCR) announced today the recipients of the AACR-Novocure Grants for Tumor Treating Fields Research program. The program represents a joint effort between Novocure and the American
![Premier Inc. Recommends FDA, DEA Reforms to Prevent Drug Shortages](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Premier Inc. Recommends FDA, DEA Reforms to Prevent Drug Shortages
Premier Inc. (NASDAQ: PINC) today provided the U.S. Food and Drug Administration (FDA) and the U.S. Drug Enforcement Administration (DEA) with a list of reforms and regulatory waivers that the
![First Patient Enrolled in Novocure’s EF-33 Phase 2 Pilot Trial of Tumor Treating Fields Delivered Utilizing High-Intensity Transducer Arrays](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
First Patient Enrolled in Novocure’s EF-33 Phase 2 Pilot Trial of Tumor Treating Fields Delivered Utilizing High-Intensity Transducer Arrays
Novocure (NASDAQ: NVCR) announced today that the first patient has been enrolled in its EF-33 phase 2 pilot trial of Tumor Treating Fields delivered utilizing high-intensity arrays in patients with
![Virginia Mason Health System Partners with Premier Inc. to Manage Supply Chain and Enhance Expense Management](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Virginia Mason Health System Partners with Premier Inc. to Manage Supply Chain and Enhance Expense Management
Virginia Mason Health System, a leading non-profit regional healthcare system serving the Pacific Northwest, and Premier Inc. (NASDAQ: PINC), a healthcare improvement company, have partnered to
![Novocure Announces Clinical Trial Collaboration with MSD to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Non-Small Cell Lung Cancer](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Novocure Announces Clinical Trial Collaboration with MSD to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Non-Small Cell Lung Cancer
Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with MSD (a tradename of Merck & Co., Inc.), through a subsidiary, to develop Tumor Treating
![Charles River Laboratories Schedules Second-Quarter 2020 Earnings Release and Conference Call](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Charles River Laboratories Schedules Second-Quarter 2020 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2020 financial results on Wednesday, August 5th, before the market opens. A conference call has been scheduled
![Premier Inc. ProvideGx™ Program Partners with Fresenius Kabi to Secure the Supply of Sedation Drug Essential for COVID-19 Care](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Premier Inc. ProvideGx™ Program Partners with Fresenius Kabi to Secure the Supply of Sedation Drug Essential for COVID-19 Care
Premier Inc. (NASDAQ: PINC), through its ProvideGx™ program, has partnered with Fresenius Kabi to supply Diprivan® (propofol) injectable emulsion, USP to healthcare providers, helping to stabilize
![Chemed To Report Second-Quarter 2020 Earnings July 29, Related Conference Call To Be Held On July 30](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Chemed To Report Second-Quarter 2020 Earnings July 29, Related Conference Call To Be Held On July 30
Chemed Corporation (NYSE:CHE) today announced that it will release financial results for the second quarter ended June 30, 2020, on Wednesday, July 29, 2020, following the close of trading on the
![Xencor and Atreca Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Xencor and Atreca Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, and Atreca, Inc. (Atreca)
![Novocure Announces Over 100 Physicians in the U.S. Now Certified to Prescribe Optune Lua™](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Novocure Announces Over 100 Physicians in the U.S. Now Certified to Prescribe Optune Lua™
Novocure (NASDAQ: NVCR) today announced that over 100 physicians from more than 50 cancer treatment centers in the U.S. are now certified to prescribe Optune Lua, which is approved for the
![Novocure Enrolls Last Patient in HEPANOVA Trial Testing Tumor Treating Fields in Combination with Sorafenib in Advanced Liver Cancer](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Novocure Enrolls Last Patient in HEPANOVA Trial Testing Tumor Treating Fields in Combination with Sorafenib in Advanced Liver Cancer
Novocure (NASDAQ: NVCR) today announced that the last patient has been enrolled in the HEPANOVA trial, a phase 2 pilot trial testing Tumor Treating Fields in combination with sorafenib in patients
![Novocure to Report Second Quarter 2020 Financial Results](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Novocure to Report Second Quarter 2020 Financial Results
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2020 on Thursday, July 30, 2020, before the U.S. financial markets open. Novocure’s management
![Premier Inc. Calls for National Stockpiling Standards to Prevent Redundant Efforts, Next Wave of Product Shortages](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Premier Inc. Calls for National Stockpiling Standards to Prevent Redundant Efforts, Next Wave of Product Shortages
Nearly 90 percent of healthcare providers are contributing to stockpiles of critical medical supplies and drugs intended to last as long as 90 days, according to a recent survey conducted by
![Premier Inc. Survey: Alternate Site Providers Report Increased PPE Needs but Face Challenges with Traditional Distribution Channels](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Premier Inc. Survey: Alternate Site Providers Report Increased PPE Needs but Face Challenges with Traditional Distribution Channels
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today released survey results finding that the majority of alternate site providers, including senior living facilities
![Xencor Presents Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Xencor Presents Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced the